MENU
+Compare
CYTK
Stock ticker: NASDAQ
AS OF
May 9, 04:59 PM (EDT)
Price
$31.69
Change
-$0.79 (-2.43%)
Capitalization
3.88B

CYTK Cytokinetics Forecast, Technical & Fundamental Analysis

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining... Show more

Industry: #Biotechnology
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CYTK with price predictions
May 08, 2025

CYTK's RSI Oscillator is staying in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .

CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CYTK turned negative on May 06, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .

CYTK moved below its 50-day moving average on May 02, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CYTK entered a downward trend on April 03, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CYTK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (60.606) is normal, around the industry mean (14.243). P/E Ratio (0.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (253.449).

View a ticker or compare two or three
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CYTK is expected to report earnings to rise 4.41% to -141 cents per share on July 31

Cytokinetics CYTK Stock Earnings Reports
Q2'25
Est.
$-1.42
Q1'25
Beat
by $0.01
Q4'24
Missed
by $0.04
Q3'24
Missed
by $0.13
Q2'24
Missed
by $0.25
The last earnings report on May 06 showed earnings per share of -136 cents, beating the estimate of -137 cents. With 1.03M shares outstanding, the current market capitalization sits at 3.88B.
A.I. Advisor
published General Information

General Information

a company which engages in discovery and development of small molecule drug therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
350 Oyster Point Boulevard
Phone
+1 650 624-3000
Employees
564
Web
https://www.cytokinetics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
OBTC29.020.88
+3.13%
Osprey Bitcoin Trust
HYS92.810.03
+0.03%
PIMCO 0-5 Year High Yield Corp Bd ETF
HIO3.82N/A
N/A
Western Asset High Income Opportunity Fund
CHFUSD1.21N/A
N/A
Switzerland Franc - United States Dollar
AUDJPY92.50N/A
N/A
Australian Dollar - Japan Yen

CYTK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with ACLX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-1.69%
ACLX - CYTK
46%
Loosely correlated
+6.27%
IDYA - CYTK
46%
Loosely correlated
+1.96%
KRYS - CYTK
46%
Loosely correlated
+0.27%
TRDA - CYTK
43%
Loosely correlated
+5.64%
KRON - CYTK
43%
Loosely correlated
+1.33%
More